Current Studies
Please click the trial name for more information.
Prostate Cancer
Prostate Cancer Treatment (NCT04122976)
Sponsor: Bayer
Summary: Darolutamide for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) for whom a decision to treat with darolutamide has been made before enrollment.
Requirements:
- Participant must be ≥ 18 years of age
- Patients with castrate-resistant prostate cancer that has not spread throughout the body
Detection of Prostate Cancer Recurrence (NCT05249127)
Sponsor: Clarity Pharmaceuticals
Summary: Eligible participants will receive a single administration of 64Cu-SAR-bisPSMA followed by a positron emission tomography (PET)/computed tomography (CT) scan that is clinically suitable in the detection of prostate cancer and in detecting small lesions over time.
Requirements:
- Participant must be ≥ 18 years of age
- Rising PSA after definitive therapy (removal of prostate, radiation, brachytherapy)
- Cannot be taking medications for prostate cancer (androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist)
Prostate Cancer Treatment (NCT05204927)
Sponsor: Curium
Summary: Patients with metastatic castrate-resistant prostate cancer who have failed androgen receptor therapy will be randomized to receive either novel PSMA radiopharmaceutical 177Lueticium or active control (enzalutamide or abiraterone) to assess overall survival.
Requirements:
- Participant must be ≥ 18 years of age
- Patients with prostate cancer that has spread to other parts of the body
- Previous treatment with abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), or darolutamide (Nubeqa)
- No prior chemotherapy treatment
Prostate Cancer Treatment (NCT05288166)
Sponsor: Eli Lilly and Company
Summary: Phase 3 study to assess the safety and efficacy of adding abemaciclib to abiraterone (Xtandi) plus prednisone in patients with high-risk metastatic hormone-sensitive prostate cancer.
Requirements:
- Participant must be ≥ 18 years of age
- Presence of ≥4 bone metastases and/or ≥1 visceral metastases
- Cancer has spread to bones or other organs
- Participants must have initiated ADT (androgen deprivation therapy)
Prostate Cancer Treatment (NCT03850795)
Sponsor: Hinova Pharmaceuticals
Summary: Enrolling patients with metastatic castrate-resistant prostate cancer to evaluate the efficacy and safety of HINOVA drug against enzalutamide (Xtandi) in asymptomatic or mildly symptomatic patients with progressive metastatic prostate cancer.
Requirements:
- Participant must be ≥ 18 years of age
- Progressive disease characterized by rising PSA levels or cancer spreading to other parts of the body (metastasis)
Prostate Cancer Treatment (NCT04382898)
Sponsor: BioNTech SE
Summary: mRNA vaccine therapy that targets prostate cancer antigens with the antibody Cemiplimab. This study is for patients with a new diagnosis of prostate cancer who are going to have their prostate removed or for patients who have failed one line of androgen receptor therapy and cancer has spread to other parts of the body.
Requirements:
- Depends on cohort
Prostate Cancer Treatment (NCT04729114)
Sponsor: Propella Therapeutics, Inc.
Summary: This is a Phase 1/2a study of i.m. PRL-02 depot in patients with advanced prostate cancer.
Requirements:
- Depends on cohort
Prostate Cancer Treatment (NCT05059236)
Sponsor: Bayer
Summary: Treatment for high-risk biochemical recurrent prostate cancer in patients that have received initial treatment for their cancer (i.e. Prostatectomy (removal of prostate), prostatectomy and radiation, or radiation alone)
Requirements:
- Male ≥18 years of age at the time of signing the informed consent
- High-risk biochemical recurrence (BCR), defined as rising PSA levels
Exclusions:
- Not able to receive contrast agents for MRI, CT, or PSMA PET/CT imaging
- Other cancer diagnoses
- History procedure in which both testicles were removed
Bladder Cancer
Bladder Cancer Treatment (NCT04640623)
Sponsor: Janssen Research & Development, LLC
Summary: A Phase 3 Study Evaluating the Efficacy and Safety of TAR-200 in combination with Cetrelimab, TAR-200 alone, or Cetrelimab alone in participants with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) who show no response to intravesical Bacillus Calmette-Guérin (BCG).
Requirements:
- 18 years or older
- Diagnosed with NMIBC
- Unresponsive to intravesical Bacillus Calmette-Guerin (BCG) therapy
- Ineligible for or have decided not to undergo radical cystectomy
Bladder Cancer Treatment (NCT03945162)
Sponsor: Theralase Technologies, Inc.
Summary: The goal of this study is to destroy tumor cells through photodynamic therapy in bladder cancer patients who have been through BCG.
Requirements:
- 18 years or older
- Bladder cancer has not spread throughout the body (metastasis)
- Patients must have had prior BCG therapy
- Must not have UTI
Bladder Cancer Treatment (NCT05316155)
Sponsor: Janssen, Inc.
Summary: Phase 1 study of TAR-210 in participants with non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) with specific FGFR mutations or fusions to evaluate anti-tumor activity
Requirements:
- 18 years or older
- Bladder cancer that has previously been treated but has now recurred
- Patients may or may not have had BCG therapy
Bladder Cancer Treatment (NCT03711032)
Sponsor: Merck Sharp & Dohme Corp.
Summary: A Phase 3 trial of BCG therapy with or without pembrolizumab (MK-3475) for high-risk non-muscle invasive bladder cancer that is either persistent or recurrent following BCG induction or naive to BCG.
Requirements:
- 18 years or older
- Must have undergone cystoscopy/TURBT
- History of muscle-invasive bladder cancer not permitted
Bladder Cancer Treatment (NCT04700124)
Sponsor: Merck Sharp & Dohme Corp.
Summary: A Phase 3 to evaluate pembrolizumab (MK-3475) versus neoadjuvant gemcitabine and cisplatin in participants with muscle-invasive bladder cancer (MIBC).
Requirements:
- 18 years or older
- Has NOT received any prior systemic treatment, chemoradiation, and/or radiation therapy treatment for MIBC
Sponsor: Janssen Research and Development, LLC
Summary: Phase 2 Study of TAR-200 in Combination with Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Chemotherapy.
Requirements:
- 18 years or older
- Must not have received prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy within 2 years prior
Bladder Cancer Treatment (NCT04700124)
Sponsor: Merck Sharp & Dohme LLC
Summary: Phase 3 study to evaluate perioperative Enfortumab Vedotin plus Pembrolizumab (MK-3475) versus neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible participants with Muscle-invasive Bladder Cancer (MIBC).
Requirements:
- Bladder cancer that has invaded the bladder muscle but has not spread outside the bladder (other organs, bones, or lymph nodes)
- Eligible for cystectomy (removal of the bladder)
- No previous bladder therapies
Bladder Cancer Treatment (NCT05714202)
Sponsor: Janssen Research & Development, LLC
Summary: Phase 3 study evaluating the efficacy and safety of TAR-200 in combination with Cetrelimab or TAR-200 alone vs Intravesical Bacillus Calmette-Guérin (BCG) in patients with BCG naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC).
Requirements:
- Participant must be ≥ 18 years of age
- Newly diagnosed high risk non muscle invasive bladder cancer
- No previous bladder cancer treatment
Biomarkers
Prostate Cancer Detection
Sponsor: Gregor Diagnostics
Summary: Semen Sample Collection and Processing for use in the Development of Prostate Cancer Diagnostic Tests
Requirements:
- Participant must be between 50 and 70 years of age
- Never received treatment for prostate cancer
- Healthy enough for sexual activity
Compensation: $100 gift card when you submit the sample
Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hypertrophy Treatment (NCT05400980)
Sponsor: Prodeon Medical, Inc
Summary: An implantable device for the treatment of lower urinary tract symptoms associated with Benign Prostatic Hyperplasia (BPH) in men.
Requirements:
- Men ≥ 45 years of age at the time of signing the informed consent
- BPH diagnosis
Exclusions:
- Previous BPH procedure (e.g., prostate surgery, stent implants, any invasive treatment to the prostate)
- Biopsy of the prostate within past 8 weeks.
- Prostate cancer or bladder cancer
Urinary Urge Incontinence
Urinary Urge Incontinence Treatment (NCT05250908)
Sponsor: Coloplast A/S
Summary: An implantable device for the treatment of overactive bladder symptoms of Urinary Urge Incontinence (UUI) in men and women who have failed or cannot tolerate conservative therapy.
Requirements:
- Women and men age 22-80 years old
- Greater than 6-month history of UUI diagnosis
- Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management)
Exclusions:
- Diagnosis of stress urinary incontinence or mixed urinary incontinence (stress incontinence symptoms include urinary leaks when coughing/laughing/sneezing)
- History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain)
- Benign prostatic hyperplasia (BPH) diagnosis
Ear, Nose, and Throat
ENT Cancer Treatment (NCT03765918)
Sponsor: Merck Sharp & Dohme LLC
Summary: Phase 3 randomized study of pembrolizumab given prior to surgery and in combination with standard-of-care radiotherapy as post-surgical therapy in treatment naïve patients with newly diagnosed Stage III/IVA advanced head and neck squamous cell carcinoma.
Requirements:
- Participant must be ≥ 18 years of age
- Newly diagnosed head or neck squamous cell carcinoma with no previous treatment
- Eligible for surgery
ENT Treatment (NCT04684524)
Sponsor: Sanofi
Summary: Randomized study assessing the efficacy and safety of Dupilumab in patients with Allergic Fungal Rhinosinusitis (AFRS)
Requirements:
- Diagnosis of Allergic Fungal Rhinosinusitis (AFRS) with confirmed nasal polyps
- No current nasal cavity cancer
- No prior history of treatment with Dupilumab in the past year
Note to Study Participants
While qualified participants will not be paid for their participation, they will receive all study related medication, visits and tests at no cost depending on requirements of each study individually.